drugset / Trial / NCT06093269

Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)

NCT06093269

Phase 4 Active not recruiting 32 enrolled University Hospital, Tours
NaSingle-groupOpen-labelTreatment

Summary

In chronic hemodialysis patients, bacteremia is most commonly caused by dialysis catheter infections. It is estimated that the vast majority (52-84%) of these infections are due to Gram-positive cocci, particularly Staphylococcus aureus (21-43%). Penicillin M (oxacillin and cloxacillin in France) is the reference beta-lactam for the treatment of invasive methicillin-sensitive S. aureus (MSSA) infections, but has not shown a prognostic benefit in large retrospective cohorts comparing penicillin M and cefazolin, at the expense of more frequent adverse events. Dosage in the chronic hemodialysis population is unclear because it is based on old studies.

Timeline

Start
2023-11-20
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefazolin Small molecule 20 mg/kg Other